Literature DB >> 77421

Altered theophylline pharmacokinetics during acute respiratory viral illness.

K C Chang, T D Bell, B A Lauer, H Chai.   

Abstract

The plasma half-life of theophylline was determined during and 1 month after serologically confirmed upper-respiratory-tract viral illness in six children with chronic asthma. In this group the plasma-theophylline half-life (mean = 419.8 min) was significantly longer during the acute stage of their illness than 1 month later (mean 249.9 min). There was no appreciable change in half-life in 4 patients who were febrile but in whom seroconversion did not occur. These preliminary results suggest that certain upper-respiratory-tract viral infections may affect theophylline metabolism.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 77421      PMCID: PMC7135825          DOI: 10.1016/s0140-6736(78)90305-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  2 in total

1.  An ultraviolet spectrophotometric method for the determination of theophylline and theobromine in blood and tissues.

Authors:  J A SCHACK; S H WAXLER
Journal:  J Pharmacol Exp Ther       Date:  1949-11       Impact factor: 4.030

2.  Variation in theophylline clearance rate with time in chronic childhood asthma.

Authors:  P Leung; A Kalisker; T D Bell
Journal:  J Allergy Clin Immunol       Date:  1977-06       Impact factor: 10.793

  2 in total
  56 in total

Review 1.  [Clinically relevant pharmacokinetic drug interactions in the intensive care unit: an overview].

Authors:  W Kämmerer
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-03-23       Impact factor: 0.840

Review 2.  Vaccine-Drug Interactions: Cytokines, Cytochromes, and Molecular Mechanisms.

Authors:  Paolo Pellegrino; Cristiana Perrotta; Emilio Clementi; Sonia Radice
Journal:  Drug Saf       Date:  2015-09       Impact factor: 5.606

Review 3.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

4.  Depression of drug metabolizing activity in the human liver by interferon-alpha.

Authors:  H Okuno; Y Kitao; M Takasu; H Kano; K Kunieda; T Seki; Y Shiozaki; Y Sameshima
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Infections and possible vaccine-drug interactions.

Authors:  Kari Raaska; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2014-05-08       Impact factor: 2.953

6.  Enprofylline disposition in the presence and absence of amoxycillin or erythromycin.

Authors:  D S Sitar; F Y Aoki; D J Hoban; K G Hidinger; P R Montgomery; P A Mitenko
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

Review 7.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

8.  Combination of aminophylline (Phyllocontin Continus tablets) and salbutamol in the management of chronic obstructive airways disease.

Authors:  C J Clark; G Boyd
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

9.  Variability in drug metabolizing enzyme activity in HIV-infected patients.

Authors:  Amanda E Jones; Kevin C Brown; Rebecca E Werner; Karl Gotzkowsky; Andrea Gaedigk; Mike Blake; David W Hein; Charles van der Horst; Angela D M Kashuba
Journal:  Eur J Clin Pharmacol       Date:  2010-01-19       Impact factor: 2.953

Review 10.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.